The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Thu, 12th Dec 2019 14:23

(Alliance News) - The four Oxford Technology venture capital trusts on Thursday reported mixed performances in the third quarter of the current financial year.

Oxford Technology VCT PLC said its net asset value per share as at the end of November stood at 43.9 pence, down from 49.5p as at August 31. This decrease is attributable to the drop in the share price of Scancell Holdings PLC and a fall in the valuation of Getmapping and Select, the company explained.

Oxford Technology VCT shares were untraded in London on Thursday, last closing at 28.50p each.

Oxford Technology 2 VCT PLC also said its NAV performance deteriorated over the third quarter, with NAV per share at November 30 of 30.7p compared to 32.8p as at the end of August. This decrease is attributable to a decline in the valuation of Orthogem and, as for its stable-mate, the drop in the share price of Scancell.

The stock was trading 12% higher at 28.00p a share.

Oxford Technology 4 VCT PLC reported NAV per share as at the end of November of 41.9p, down from 40.4p as at the end of August. This decrease is as a result of a fall in the share price of Castleton Technology PLC, as well as decreases in the valuations of Orthogem and Select.

Oxford Technology 4 VCT shares were untraded at 26.50p each.

By contrast, Oxford Technology 3 VCT PLC said its NAV per share grew to 106.9p at the end of November from 97.8p as of August 31. This increase is due to continuing positive news from Ixaris

and good overall progress by Arecor, the company explained.

The stock was untraded at 48.50p a share.

Scancell shares are down 45% so far in 2019, while Castleton shares are down 22%.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
22 Jul 2020 11:24

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

Read more
24 Jun 2020 12:18

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Read more
12 Jun 2020 12:59

Scancell upbeat on publication of AvidiMab research

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.

Read more
28 Apr 2020 16:40

Director dealings: Scancell director lowers stake

(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.

Read more
28 Apr 2020 14:43

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Read more
24 Apr 2020 12:00

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Read more
24 Apr 2020 10:49

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Read more
3 Feb 2020 14:20

Scancell's 'SCIB1' clears latest regulatory hurdle in US

(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.

Read more
3 Feb 2020 10:44

Scancell Gets US FDA Approval For SCIB1 Drug Application

Scancell Gets US FDA Approval For SCIB1 Drug Application

Read more
31 Jan 2020 11:12

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Read more
20 Jan 2020 12:04

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Read more
18 Dec 2019 16:29

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

Read more
16 Dec 2019 13:30

Scancell inks AvidiMab agreement with Chinese biotech company

(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.

Read more
16 Dec 2019 09:21

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.